	US 11,773,147 B2
	Lipocalin muteins with binding affinity for LAG-3
Christine Rothe, Dachau (DE); Shane Olwill, Freising (DE); Andrea Allersdorfer, Wolnzach (DE); Timo Eichner, Freising (DE); Rachida Siham Bel Aiba, Munich (DE); and Marina Pavlidou, Freising (DE)
Assigned to Pieris Pharmaceuticals GmbH, Hallbergmoos (DE)
Filed by Pieris Pharmaceuticals GmbH, Freising (DE)
Filed on Oct. 12, 2021, as Appl. No. 17/499,640.
Application 17/499,640 is a division of application No. 16/478,465, granted, now 11,168,119, previously published as PCT/EP2018/051139, filed on Jan. 18, 2018.
Claims priority of application No. 17151945 (EP), filed on Jan. 18, 2017.
Prior Publication US 2022/0098253 A1, Mar. 31, 2022
Int. Cl. C07K 14/47 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/47 (2013.01) [G01N 33/6872 (2013.01); A61K 38/00 (2013.01); C07K 2318/20 (2013.01); G01N 2333/70503 (2013.01)]

20 Claims

1. A lipocalin mutein that is capable of binding lymphocyte-activation protein 3 (LAG-3), wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 20-28,

wherein the amino acid sequence of the mutein comprises the following amino acid mutations in comparison with the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1): Ser 14→Pro; Asp 25→Ser; Phe 28→Asp; Lys 52→Arg; Met 55→Val; Ser 58→Asp; Ala 66→Asn; Ala 79→Glu; Ala 86→Asp; Cys 101→Phe; Leu 105→Gly; Lys 108→Thr; Lys 114→Ala; Lys 121→Thr, and

wherein the amino acid sequence of the mutein further comprises at least one of the following mutated amino acid residues in comparison with the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1): Arg 26→Ser, Asp, Glu, or Ala; Met 31→Leu; Asn 32→Thr; His 84→Tyr or Leu; His 106→Glu, Lys, or Pro; Val 110→Asn; Gly 112→Val or Leu; Val 113→Ala or Leu.